Stuart A Arbuckle Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Stuart A Arbuckle is EVP, COO of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 49,691 shares of VRTX, which is worth approximately $25.7 Million. The most recent transaction as insider was on Feb 01, 2023, when has been sold 38,221 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.7K

0% 3M change

12.14% 12M change

Total Value Held $25.7 Million

Stuart A Arbuckle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 01 2023	BUY Grant, award, or other acquisition	-	38,221 Added 28.42%	96,252 Common Stock
Dec 06 2022	BUY Grant, award, or other acquisition	-	12,753 Added 18.02%	58,031 Common Stock
Aug 15 2022	SELL Open market or private sale	$6,719,527 $303.05 p/Share	22,173 Reduced 32.87%	45,278 Common Stock
Aug 15 2022	BUY Exercise of conversion of derivative security	$1,022,251 $155.57 p/Share	6,571 Added 8.88%	67,451 Common Stock
Aug 10 2022	SELL Open market or private sale	$54,211 $301.17 p/Share	180 Reduced 0.29%	60,880 Common Stock
Aug 10 2022	BUY Exercise of conversion of derivative security	$9,956 $155.57 p/Share	64 Added 0.1%	61,060 Common Stock
Aug 09 2022	SELL Open market or private sale	$1,712,576 $300.98 p/Share	5,690 Reduced 8.53%	60,996 Common Stock
Aug 09 2022	BUY Exercise of conversion of derivative security	$299,628 $155.57 p/Share	1,926 Added 2.81%	66,686 Common Stock
May 16 2022	SELL Open market or private sale	$33,299 $250.37 p/Share	133 Reduced 0.2%	64,760 Common Stock
May 02 2022	SELL Open market or private sale	$80,778 $263.98 p/Share	306 Reduced 0.47%	64,760 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$1,651,074 $227.86 p/Share	7,246 Reduced 10.02%	65,066 Common Stock
Feb 17 2022	SELL Payment of exercise price or tax liability	$959,336 $232.51 p/Share	4,126 Reduced 5.4%	72,312 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$722,730 $237.74 p/Share	3,040 Reduced 3.82%	76,438 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	38,375 Added 32.56%	79,478 Common Stock
Nov 15 2021	SELL Open market or private sale	$562 $187.4 p/Share	3 Reduced 0.01%	41,103 Common Stock
May 17 2021	SELL Open market or private sale	$23,575 $216.28 p/Share	109 Reduced 0.26%	41,103 Common Stock
Feb 25 2021	SELL Open market or private sale	$777,676 $214.0 p/Share	3,634 Reduced 8.12%	41,103 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$630,518 $217.57 p/Share	2,898 Reduced 6.08%	44,737 Common Stock
Feb 18 2021	SELL Open market or private sale	$1,658,039 $211.89 p/Share	7,825 Reduced 14.11%	47,635 Common Stock
Feb 17 2021	SELL Payment of exercise price or tax liability	$1,321,320 $211.75 p/Share	6,240 Reduced 10.11%	55,460 Common Stock
Feb 11 2021	SELL Open market or private sale	$1,089,102 $211.23 p/Share	5,156 Reduced 7.71%	61,700 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$664,110 $214.16 p/Share	3,101 Reduced 4.43%	66,856 Common Stock
Feb 03 2021	SELL Open market or private sale	$332,944 $214.25 p/Share	1,554 Reduced 2.17%	69,957 Common Stock
Feb 03 2021	BUY Exercise of conversion of derivative security	$134,452 $86.52 p/Share	1,554 Added 2.13%	71,511 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	34,778 Added 33.21%	69,957 Common Stock

Also insider at

RYTM

RHYTHM PHARMACEUTICALS, INC. Healthcare

Director

IMGN

ImmunoGen, Inc. Healthcare

Director

SAA